missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ FL - SRC 3-1 Peptide, 100μM

Contains known interaction motifs and labeled with fluorescein. Invitrogen™ Fluorescein-SRC 3-1 Peptide, 100μM is matched to complement the LanthaScreen™ TR-FRET Nuclear Receptor Coregulator Assays to enable primary or secondary screening of nuclear receptor agonists and antagonists.

Brand:  Invitrogen™ PV4590

Product Code. 10434095

  • 190.00 € / Each

Please to purchase this item. Need a web account? Register with us today!

Explore more special offers
This item is not returnable. View return policy

Description

Description

Ligand binding to nuclear receptors causes conformational changes in the receptor, resulting in a cascade of events, including dissociation of repressor proteins, association of coactivator proteins, and assembly of pol II and other transcriptional factors for activation of target genes. TR-FRET based assays can be developed using the LanthaScreen™ panel of fluorescein-labeled coregulator peptides to investigate conformational changes of nuclear receptors upon ligand binding, either by determining the affinity of ligand-bound receptor for different coregulator peptides, or by identifying additional agonists or antagonists via displacement or recruitment of a specific coregulator peptide.

In the LanthaScreen™ TR-FRET RXR beta Coactivator Assay, a terbium (Tb)-labeled anti-GST antibody is used to indirectly label GSTtagged RXR beta protein. An agonist (9-cis Retinoic Acid) added to the receptor which, upon ligand binding, causes a conformational change resulting in recruitment of the Fl-D22 coactivator peptide. The binding of the fluorescent coregulator peptide to RXR beta causes an increase in the TR-FRET emission ratio.

TRUSTED_SUSTAINABILITY
Specifications

Specifications

Store in freezer (-5 to -30°C).
Classic Dyes
100 μL
Dry Ice
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

For Research Use Only. Not for use in diagnostic procedures.